http://www.acc.org/Feed?clinicalTopicID=2db4bea0-4bbc-4fbd-b7b4-0e144f74ae32 Clinical Topic Feed: Nonstatins en /Latest-in-Cardiology/Articles/2026/09/01/01/JACC-in-a-Flash Featured topics and Editors' Picks from all of ACC's JACC Journals. 1788264600000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/24/12/30/sat-jacc-journals-esc-2026 Several abstracts and e-posters presented at ESC Congress 2026 and simultaneously published across the JACC family of journals highlight the expanding role of precision medicine, novel therapeutics, and advanced risk stratification across cardiovascular care. 1788002340000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/24/12/30/sat-215am-staree-esc-2026 Among community-dwelling older adults, treatment with atorvastatin demonstrated a 30% relative reduction in major cardiovascular events over roughly six years compared with placebo but did not result in longer disability-free survival, based on findings from the STAREE trial presented at ESC Congress 2026 and simultaneously published in NEJM. 1787991840000 Articles and Stories /Latest-in-Cardiology/Articles/2026/08/17/15/29/A-Rare-Pattern-of-Harm Statin therapy remains a cornerstone in the prevention of cardiovascular (CV) morbidity and mortality. Although statin-associated muscle symptoms are relatively common and often self-limited, severe statin-associated immune-mediated necrotizing myopathy (IMNM) has emerged as a rare but important clinical entity. 1786989360000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/08/10/15/19/Long-Term-ASCVD-Risk Nearly 25 million more adults in the U.S. are eligible for statin therapy, based on recommendations in the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline, compared with the previous guideline, according to original research published Aug. 12 in JACC. 1786544280000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/08/05/20/14/GBD-Study-2023 The global burden attributable to elevated LDL-C has grown substantially since 1990, driven largely by population growth and aging despite significant declines in age-standardized rates, according to findings from the Global Burden of Disease Study 2023 (GBD 2023) Cholesterol Collaborators published July 29 in JAMA. 1786042800000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/07/28/17/19/NHANES-Analyses Three studies using National Health and Nutrition Examination Survey (NHANES) data published July 20 in JAMA provide new insights into LDL-C treatment goals under the 2026 ACC/AHA Guideline on the Management of Dyslipidemia. 1785351240000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/07/20/14/38/GBD-2023 Nearly 90% of ischemic heart disease (IHD) deaths in 2023 in the U.S. were attributable to modifiable risk factors, led by high systolic blood pressure (SBP), dietary risks and high LDL-C, according to data from the Global Burden of Disease Study 2023 (GBD 2023), published July 15 in JAMA Cardiology. 1784735640000 Articles and Stories /Latest-in-Cardiology/Articles/2026/07/21/12/01/FDA-Update The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, to lower LDL cholesterol in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). 1784635560000 Articles and Stories /Latest-in-Cardiology/Articles/2026/07/01/12/47/eagles-eye-view-01jul2026 In this week’s View, Dr. Eagle looks at how genotype independently predicts heart failure outcomes in patients with hypertrophic cardiomyopathy (HCM). 1782910140000 Articles and Stories